Back to all presentations

Preclinical data presented at, Clinical Trials in Alzheimer’s Disease (CTAD) 2022

Date: 2022-12-02

Dr. Anders Sandberg, Chief Scientific Officer, presented data for the Company's preclinical antibody candidate ALZ-201. The poster summarises the development of the monoclonal antibody ALZ-201 and its unique binding profile in relation to other drug candidates in development.

The data show that ALZ-201 differs significantly from lecanemab, aducanumab, and gantenerumab in that, unlike these, binds specifically to a small portion of the amyloid beta known as oligomers. With this targeted binding profile, ALZ-201 has a strong neutralising effect on the toxic form of amyloid beta extracted from the brains of deceased Alzheimer’s patients. Specificity for the amyloid beta that is toxic, is thought to be necessary to obtain a good therapeutic effect in patients with Alzheimer’s disease. The data were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) 2022 on 29 November to 2 December.

View poster